CAS NO: | 1744-22-5 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
50mg | 电议 |
100mg | 电议 |
500mg | 电议 |
1 g | 电议 |
5 g | 电议 |
10 g | 电议 |
生物活性 | Riluzole is an anticonvulsant drug and belongs to the family of use-dependentNa+channelblocker which can also inhibitGABAuptake with anIC50of 43 μM. | ||||||||||||||||
IC50& Target | Sodium channel[1]IC50: 43 μM (GABA receptor)[1] | ||||||||||||||||
体外研究 (In Vitro) | Riluzole is an anticonvulsant drug and belongs to the family of use-dependent Na+channel blocker which can also inhibit GABA uptake with an IC50of 43 μM. At 20 μM, Riluzole inhibits peak autaptic IPSCs only slightly but prolongs IPSCs reliably. It is also found that Riluzole causes a strong, concentration-dependent, readily reversible enhancement of responses to 2 μM GABA. At higher concentrations of Riluzole, especially 300 μM, GABA currents exhibit apparent desensitization during prolonged co-exposure to 2 μM GABA and Riluzole. The EC50of Riluzole potentiation of GABA responses is about 60 μM[1]. | ||||||||||||||||
体内研究 (In Vivo) | In normal naive rats, systemic injection of Riluzole (8 mg/kg, i.p.; n=6 rats) decreases the duration of ultrasonic but not audible vocalizations evoked by noxious stimulation of the knee joint compare to vehicle tested in the same rats (P<0.05). Systemic application of Riluzole (8 mg/kg, i.p.; n=19 rats) decreases the vocalizations of arthritic rats compare to predrug and vehicle significantly (P<0.05 to 0.001). Riluzole administered into the CeA significantly decreases the duration of audible and ultrasonic vocalizations evoked by noxious stimulation of the knee compare to predrug values (n=8 rats; P<0.05 to 0.01)[2]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 234.20 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C8H5F3N2OS | ||||||||||||||||
CAS 号 | 1744-22-5 | ||||||||||||||||
中文名称 | 利鲁唑 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 100 mg/mL(426.99 mM;Need ultrasonic) H2O : 1 mg/mL(4.27 mM;ultrasonic and adjust pH to 3 with HCl) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|